Physicians' Academy for Cardiovascular Education

Early Initiation of antiplatelet therapy:Pre-treatment in ACS, facts and fictions

June 23, 2013

Presentations and webcasts of this symposium will be posted soon



The educational program is developed under auspices of
Prof J Wouter Jukema on behalf of the LUMC (Leiden University Medical Centre)

Tuesday, September 3, 2013
Session 2225, Vilnius - Village 1

14.45 - 16.15 hrs

Educational objectives

  • The goal of this program is to improve the knowledge with regard to peri- and post procedural management  of ACS.
  • After attending this program, the clinician will be better able to:
  • Evaluate the cardiovascular risk associated with ACS
  • Describe current treatment options for ACS and assess the proportion of patients eligible for percutaneous coronary intervention (PCI)
  • Describe the need for peri- and post procedural platelet inhibition
  • Understand the role of platelet inhibition in clinical outcomes of patients with ACS undergoing PCI


14:45 – 14:50: Introduction chairmen
- J. Wouter Jukema, MD, Leiden University Medical Center, Leiden,The Netherlands
- Peter Clemmensen, MD, The Heart Center, Rigshospitalet Copenhagen, Denmark
14:50 – 15:20, The association of pretreatment with clinical outcomes in patients undergoing PCI
- Gilles Montalescot, MD, Hôpital Pitié-Salpêtrière, Paris, France
15:20 – 15:45, Everyday clinical practice experience: Case reports
- Petr Widimský, MD,  Charles University, Hospital "Royal Vineyards, Prague, Czech Republic
15:45 – 16:10,  Learnings on early initiation of antiplatelet therapy from registries
- Peter Clemmensen, MD, The Heart Center, Rigshospitalet Copenhagen, Denmark

16:10 – 16:15, Discussions & conclusions

Organized and supervized by Leiden University Medical Centre, Course director; Prof. Wouter Jukema

CME Accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for
1 hour of external CME credit(s). Each participant should claim only those hours of credit that have
actually been spent in the educational activity.

EBAC works according to the quality standards the European Accreditation for Continuing Medical
Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).


Acces to this symposium is only for delegates registered for the ESC 2013 congress
To secure a seat at the symposium please pre-register via this link


Supported by an unrestricted educational grant from Daiichi-Sankyo and Eli Lilly and company.
“In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.”


Share this page with your colleagues and friends: